SLXN Stock Summary and Trading Ideas (Silexion Therapeutics - | NASDAQ:SLXN)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Silexion Therapeutics - trades on the NASDAQ stock market under the symbol SLXN.

As of December 12, 2025, SLXN stock price declined to $2.81 with 24,022 million shares trading.

SLXN has a beta of 0.41, meaning it tends to be less sensitive to market movements. SLXN has a correlation of 0.00 to the broad based SPY ETF.

SLXN has a market cap of $8.79 million. This is considered a Sub-Micro Cap stock.

SLXN has underperformed the market in the last year with a price return of -94.4% while the SPY ETF gained +14.0%. SLXN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.0% and -0.7%, respectively, while the SPY returned +4.0% and -0.2%, respectively.

SLXN support price is $2.77 and resistance is $3.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLXN shares will trade within this expected range on the day.